Hauptseite > Nachrichten > News

Accu-Tell® COVID-19 IgG/IgM Rapid Test is reported as one of the SARS-CoV-2 commercial antibody kits which demonstrated highest sensitivity at earlier time points, while maintaining high specificities

Oct. 14, 2020
Teilen:

Accu-Tell® COVID-19 IgG/IgM Rapid Test is reported as one of the SARS-CoV-2 commercial antibody kits which demonstrated highest sensitivity at earlier time points, while maintaining specificities of 98% or above, according to a study published September 24 in the open-access journal PLOS Pathogens.

A study article named “Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings”, was published September 24 in the open-access journal PLOS Pathogens by Jonathan Edgeworth and Blair Merrick of Guy's and St Thomas' NHS Foundation Trust, Suzanne Pickering and Katie Doores of King's College London, and colleagues.

In the study, the researchers developed their own sensitive and specific antibody assay and used it to conduct unbiased, head-to-head comparisons of 10 commercial antibody test kits on an identical panel of blood samples from 110 SARS-CoV-2-positive patients admitted to hospitals with COVID-19 and 50 pre-pandemic negatives.

 

There was a broad range of performance among the tests, with specificity – the ability of the test to correctly identify those without the disease (true negative rate) – ranging from 82% to 100%, and overall sensitivity – the ability of a test to correctly identify those with the disease (true positive rate) – ranging from 60.9% to 87.3%.

 

When all commercial tests were compared, Accu-Tell® COVID-19 IgG/IgM Rapid Test is one of the three lateral flow immunoassays which demonstrated highest sensitivity at earlier time points, while maintaining specificities of 98% or above. These tests also gave the best crossassay agreements with each other and with the in-house ELISA.

 

In the research study, our Accu-Tell® COVID-19 IgG/IgM rapid test showed the following performance:

- One of the highest in the Cross comparison of overall specificities and sensitivities;

- One of the highest levels of sensitivity at less than 10 days POS.

- One of the tests which all had sensitivities above 95% for samples taken 20 days POS.

- One of the tests which demonstrated highest sensitivity at earlier time points, while maintaining specificities of 98% or above.

 

The article can be read at https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1008817 or

https://www.researchgate.net/publication/341919134_Comparative_assessment_of_multiple_COVID-19_serological_technologies_supports_continued_evaluation_of_point-of-care_lateral_flow_assays_in_hospital_and_community_healthcare_settings

 

The content of the article has been reprinted by many media:

DailyMail UK:

https://www.dailymail.co.uk/sciencetech/article-8769069/Most-accurate-coronavirus-antibody-testing-kits-revealed.html

Outbreak News Today:

http://outbreaknewstoday.com/sars-cov-2-commercial-antibody-kits-accuracy-varies-widely-according-to-researchers-72561/

ScienceDaily:

https://www.sciencedaily.com/releases/2020/09/200924141549.htm

LabPulse.com:

https://www.labpulse.com/index.aspx?sec=sup&sub=mic&pag=dis&ItemID=801704

Insight+ (Medical Journal of Australia):

https://insightplus.mja.com.au/2020/38/research-news-in-brief-133/